Valeant Pharmaceuticals Completes Acquisition Of Solta Medical

Valeant Pharmaceuticals International has completed its acquisition of aesthetic device manufacturer Solta Medical at a price of $2.92 per share in cash, or approximately $250 million in the aggregate. Pursuant to the terms of the merger agreement, the wholly owned subsidiary of VPI merged with and into Solta on January 23, 2014. Solta has become a wholly owned subsidiary of VPI, and the common stock of Solta will no longer be listed for trading on the NASDAQ Global Select Market.

More in Home